EDGAR·FLOW

Telomir Pharmaceuticals, Inc. — Form 8-K

Filed November 18, 2026 · analyzed by the 8-K Agent
8-K ▲ Likely positive significance 48/100
What the filing says
Telomir Pharmaceuticals executed a Master Services Agreement and clinical trial Work Order with Linical, a global CRO, to advance its FDA-cleared Phase 1/2 clinical trial of Telomir-Zn in advanced/metastatic triple-negative breast cancer. Clinical initiation is targeted for Q1 2027. No dollar amounts were disclosed for the CRO engagement.
Why this rating

Operational milestone enabling lead program advancement; CRO selection removes execution risk. No financing disclosed. For $18.1M company, clinical progress is material but routine for clinical-stage biotech pursuing regulatory milestones.

View original filing on SEC.gov ↗ TELO · stock on Yahoo Finance ↗

See more from November 18, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.